Compare · LIVN vs MOVE
LIVN vs MOVE
Side-by-side comparison of LivaNova PLC (LIVN) and Corvex Inc. (MOVE): market cap, price performance, sector, and recent activity on the wire.
Summary
- LIVN operates in Health Care, while MOVE operates in Technology - the two are in different parts of the market.
- LIVN is the larger of the two at $5.02B, about 30.3x MOVE ($166.0M).
- LIVN has been more active in the news (7 items in the past 4 weeks vs 3 for MOVE).
- LIVN has more recent analyst coverage (21 ratings vs 1 for MOVE).
- Company
- LivaNova PLC
- Corvex Inc.
- Price
- -
- -
- Market cap
- $5.02B
- $166.0M
- 1M return
- +20.12%
- -
- 1Y return
- +79.41%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- EDP Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 3
- Recent ratings
- 21
- 1
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Corvex Inc.
Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.
Latest LIVN
- Amendment: SEC Form SCHEDULE 13G/A filed by LivaNova PLC
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy
- LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November
- Barclays initiated coverage on LivaNova with a new price target
- LivaNova to Announce Third-Quarter 2026 Results
- SEC Form 4 filed by Chief Legal Officer Liddy Anne M.
Latest MOVE
- Corvex to Host Third Quarter 2026 Earnings Call on Thursday, November 12, 2026
- SEC Form 8-K filed by Corvex Inc.
- SEC Form 424B5 filed by Corvex Inc.
- SEC Form EFFECT filed by Corvex Inc.
- Corvex Launches Security-First AI Inference Platform for Open-Weight Models
- SEC Form S-3 filed by Corvex Inc.
- SEC Form EFFECT filed by Corvex Inc.
- Chardan Capital Markets initiated coverage on Corvex, Inc. with a new price target
- SEC Form S-8 filed by Corvex Inc.
- SEC Form D filed by Corvex Inc.